Conatus Pharmaceuticals has received Orphan Drug Designation from the FDA for the candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA’s Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions. Emricasan is a first-in-class, orally active caspase proteas...